AstraZeneca PLC
AZNHealthcare|Drug Manufacturers - General|UK
$202.83
-0.66 (-0.32%)
DCF (FCF)
$71.68
Earnings Power
$36.18
Clinical Trials (504)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03953300 Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics | Asthma | P4 | Active | 75 | RCT, Double-blind | Benralizumab, Placebo |
| NCT06422689 Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care | Asthma | P4 | Active | 1,511 | Open-label | Albuterol and budesonide inhalation aerosol |
| NCT04493853 Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency | Hormone-Sensitive Prostate Cancer | P3 | Active | 1,012 | RCT, Double-blind | Capivasertib, Abiraterone Acetate |
| NCT04075292 Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia | Untreated Chronic Lymphocytic Leukemia | P3 | Active | 155 | RCT, Open-label | Acalabrutinib, Rituximab, Chlorambucil |
| NCT06097728 MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Unresectable Pleural Mesothelioma | P3 | Recruiting | 825 | RCT, Single-blind | Volrustomig, Pemetrexed, Carboplatin, Cisplatin, Nivolumab, Ipilimumab |
| NCT03164616 Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). | Non Small Cell Lung Cancer NSCLC | P3 | Active | 1,186 | RCT, Open-label | Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin |
| NCT03875235 Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) | Biliary Tract Neoplasms | P3 | Active | 810 | RCT, Double-blind | Durvalumab, Placebo |
| NCT05348577 Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) | Prostate Cancer | P3 | Active | 1,035 | RCT, Double-blind | capivasertib, docetaxel |
| NCT04136171 CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | P3 | Active | 1,438 | RCT, Double-blind | Eplontersen, Placebo |
| NCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | ER-Positive HER2-Negative Breast Cancer | P3 | Active | 1,370 | RCT, Double-blind | AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist |
| NCT06042049 A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab | Respiratory Syncytial Virus Infections | P3 | Active | 33 | Open-label | Nirsevimab |
| NCT03043872 Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | Small Cell Lung Carcinoma Extensive Disease | P3 | Active | 987 | RCT, Open-label | Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide |
| NCT01874353 Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | Platinum Sensitive, BRCA Mutated | P3 | Active | 327 | RCT, Double-blind | Olaparib 300mg tablets, Placebo to match olaparib 300mg |
| NCT06015737 A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Cutaneous Lupus Erythematosus | P3 | Recruiting | 302 | RCT, Double-blind | — |
| NCT04529772 A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | Diffuse Large B-Cell Lymphoma | P3 | Active | 611 | RCT, Double-blind | acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin |
| NCT05764057 DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction | AMI, STEMI | P3 | Recruiting | 450 | RCT, Double-blind | Dapagliflozin propanediol (FORXIGA™/FARXIGA™1), Placebo comparator |
| NCT04704934 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | P3 | Active | 490 | RCT, Open-label | Trastuzumab deruxtecan, Ramucirumab, Paclitaxel |
| NCT06742723 A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure | Chronic Kidney Disease and Hypertension | P3 | Recruiting | 5,000 | RCT, Double-blind | Baxdrostat/dapagliflozin, Placebo/dapagliflozin |
| NCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer | P3 | Recruiting | 744 | RCT, Open-label | Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin |
| NCT06307652 Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Heart Failure and Impaired Kidney Function | P3 | Recruiting | 4,800 | RCT, Double-blind | balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin |
| NCT04116047 CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) | Oropharyngeal Cancer | P3 | Active | 785 | RCT, Open-label | Cisplatin, Durvalumab |
| NCT03903835 ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | P3 | Recruiting | 750 | RCT, Open-label | Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin, Cabazitaxel 60 mg Solution for Injection, Docetaxel Injectable Solution, Radium Chloride Ra-223, Niraparib plus Abiraterone acetate plus Prednisone, Capivasertib plus Docetaxel, Apalutamide, Darolutamide |
| NCT03997123 Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC | Triple Negative Breast Neoplasms | P3 | Active | 923 | RCT, Double-blind | Capivasertib, Paclitaxel, Placebo |
| NCT06992609 Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. | Small Cell Lung Carcinoma | P3 | Recruiting | 70 | Open-label | Durvalumab |
| NCT04176848 CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | Breast Cancer | P2 | Active | 15 | Open-label | CFI-400945, Durvalumab |
| NCT06792695 A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Recruiting | 120 | RCT, Open-label | Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab |
| NCT07109219 Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia (B-ALL) | P1P2 | Recruiting | 83 | Open-label | — |
| NCT07123454 A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | B-cell Non-Hodgkin Lymphoma | P1P2 | Recruiting | 91 | Open-label | AZD4512 |
| NCT04106115 DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr | Bladder Cancer | P1P2 | Recruiting | 64 | Open-label | Durvalumab, S-488210/S-488211 |
| NCT05498272 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | Prostate Cancer, BRCA1 Mutation | P2 | Recruiting | 32 | Open-label | Olaparib, LHRH agonist |
| NCT04728230 Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | P1P2 | Active | 63 | Open-label | Carboplatin, Durvalumab, Etoposide, Olaparib |
| NCT07149363 Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer | Small Cell Lung Cancer (SCLC) | P2 | Recruiting | 65 | Open-label | Durvalumab 50 MG/ML |
| NCT02962063 Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer | Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | P1P2 | Active | 64 | Open-label | durvalumab, carboplatin AUC 2/paclitaxel, Tremelimumab |
| NCT03704480 Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | Advanced Biliary Tract Carcinoma | P2 | Active | 106 | Open-label | Durvalumab, Tremelimumab |
| NCT06564038 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | P1P2 | Recruiting | 276 | Open-label | AZD0486, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib |
| NCT05089916 Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study | NSCLC, EGFR Positive Non-small Cell Lung Cancer | P2 | Active | 42 | Open-label | Osimertinib |
| NCT03667820 Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC | Non-small Cell Lung Cancer (NSCLC) | P2 | Active | 41 | Open-label | Osimertinib |
| NCT04410796 Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Metastatic Non-small Cell Lung Cancer | P2 | Recruiting | 571 | RCT, Open-label | Osimertinib, Carboplatin, Pemetrexed |
| NCT05982678 Basket Study for Oligo-metastatic Breast Cancer | HER2-positive Breast Cancer | P2 | Recruiting | 72 | Open-label | Trastuzumab deruxtecan |
| NCT03795207 Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) | Node; Prostate, Bone Metastases | P2 | Active | 96 | RCT, Open-label | — |
| NCT07407465 Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | Colorectal Cancer, Colorectal Adenocarcinoma | P2 | Recruiting | 42 | Open-label | Trastuzumab-Deruxtecan (T-DXd), Capecitabine, Bevacizumab |
| NCT03330847 To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | Metastatic Triple Negative Breast Cancer | P2 | Active | 273 | RCT, Open-label | Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle). |
| NCT06897748 A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils | Chronic Obstructive Pulmonary Disease (COPD) | P2 | Active | 98 | RCT, Double-blind | Placebo, Tozorakimab |
| NCT05797168 Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | Ovarian Cancer, Lung Adenocarcinoma | P1P2 | Recruiting | 506 | RCT, Open-label | AZD5335, Saruparib (AZD5305), Bevacizumab, Carboplatin, AZD9574 |
| NCT02678182 Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction | P2 | Active | 494 | RCT, Open-label | Capecitabine, MEDI4736 (Durvalumab), Trastuzumab, Rucaparib, Ramucirumab |
| NCT05215106 Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) | Early Small (cT1N0) Triple Negative Breast Cancer | P2 | Recruiting | 200 | Open-label | Durvalumab |
| NCT04716946 Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | NSCLC, Non-small Cell Lung Cancer | P2 | Active | 13 | Open-label | Durvalumab |
| NCT06530849 A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | Refractory Systemic Lupus Erythematosus | P1 | Recruiting | 18 | Open-label | GC012F Injection |
| NCT07423598 A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels | Healthy Participants | P1 | Recruiting | 40 | RCT, Double-blind | AZD0780, Placebo |
| NCT03923270 Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | P1 | Active | 25 | Open-label | Durvalumab, Tremelimumab, Olaparib Pill, Tremelimumab |
| NCT07069725 The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. | Liver Fibrosis, Hepatic Cirrhosis | P1 | Recruiting | 12 | Open-label | AZD2389 |
| NCT02546661 Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | Muscle Invasive Bladder Cancer | P1 | Active | 117 | RCT, Open-label | AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib |
| NCT07205666 The Eplontersen Pregnancy and Lactation Outcomes Study | Transthyretin Amyloidosis | Recruiting | 10 | — | — | |
| NCT06981169 PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults | Asthma, Inflammation | Recruiting | 1,500 | — | — | |
| NCT06465810 Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis | Transthyretin Amyloidosis, ATTR-CM | Recruiting | 1,850 | — | Treatment of transthyretin (ATTR) amyloidosis in observational study setting | |
| NCT06252753 Observational Study Protocol: LIVER-R | Hepatobiliary Cancers | Recruiting | 4,490 | — | — | |
| NCT06951867 Tezspire Cardiac Events PASS | Cardiovascular Events, MACE | Recruiting | 16,640 | — | Tezepelumab | |
| NCT06344910 PRagmatic Study Of Messaging to Providers of Patients With Heart Failure in Amsterdam UMC | Heart Failure With Reduced Ejection Fraction | Recruiting | 900 | — | — | |
| NCT07185100 Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR | Heart Failure With Preserved Ejection Fraction (HFPEF), Renal Dysfunction | Recruiting | 600 | — | — | |
| NCT07218536 The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt | Atypical Hemolytic Uremic Syndrome | Recruiting | 200 | — | — | |
| NCT05557487 Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration | Lung Cancer, High-Risk Cancer | Recruiting | 6,618 | — | — | |
| NCT06974981 Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry | COPD, Chronic Obstructive Pulmonary Disease | Recruiting | 420 | — | — | |
| NCT07404202 A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients | Pan-tumor(NSCLC, GYN Cancers, BTC and UC) | Recruiting | 2,100 | — | — | |
| NCT05141201 SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS) | Lupus Erythematosus, Systemic | Active | 1,620 | — | — | |
| NCT03823547 Future Optimal Research and Care Evaluation | Acute Coronary Syndrome, Myocardial Infarction | Recruiting | 99,999 | — | — | |
| NCT07481526 A Prospecitve Multicenter, Observational Registry Study | Chronic Kidney Disease | Recruiting | 3,000 | — | — | |
| NCT05645172 Retention Rate of Acalabrutinib in a Non-interventional Setting | Chronic Lymphocytic Leukaemia (CLL) | Active | 137 | — | — | |
| NCT07113223 Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION) | Heart Failure, Cardiovascular Risk Factors | N/A | Recruiting | 1,968 | RCT, Single-blind | — |
| NCT07330245 Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab. | Lupus Erythematosus, Systemic | Recruiting | 218 | — | Anifrolumab | |
| NCT06491862 RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil | Non-squamous Non-Small Cell Lung Cancer | Recruiting | 250 | — | — | |
| NCT04746950 ALICIA (Acalabrutinib in CLL Therapy) | Chronic Lymphocytic Leukemia | Active | 90 | — | — | |
| NCT06073574 CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Active | 150 | — | — | |
| NCT00537771 Liver Safety Under Upfront Arimidex vs Tamoxifen | Breast Cancer | P4 | Completed | 384 | RCT, Open-label | Anastrozole, Tamoxifen |
| NCT01579916 A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults | Influenza | P4 | Completed | 303 | RCT, Double-blind | Trivalent Influenza Virus Vaccine |
| NCT02532309 A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques | Carotid Atherosclerosis | P4 | Unknown | 308 | RCT, Open-label | Rosuvastatin (5mg，10mg，20mg), Rosuvastatin 5mg |
| NCT00335699 Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome | Hypercholesterolemia | P4 | Completed | 370 | RCT, Open-label | Rosuvastatin |
| NCT00631189 Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients | Type IIa and IIb Hypercholesterolaemia | P4 | Completed | 668 | RCT, Double-blind | Rosuvastatin, Pravastatin, Atorvastatin |
| NCT07357597 An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. | Stomatitis | P4 | Not Yet Recruiting | 100 | Open-label | Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) |
| NCT00702325 Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans | Asthma | P4 | Completed | 311 | RCT, Double-blind | Budesonide / formoterol fumarate (SYMBICORT), Budesonide |
| NCT01119768 Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients | Non Erosive Reflux Disease, Chronic Gastritis | P4 | Completed | 305 | RCT, Open-label | Esomeprazole, Esomeprazole |
| NCT02132286 Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression | Major Depressive Disorder | P4 | Completed | 57 | RCT, Double-blind | Quetiapine XR (extended release) |
| NCT00718406 Pain Relief of Metoprolol Versus Metoprolol Plus Morphine in Acute Chest Pain | Acute Coronary Syndromes | P4 | Completed | — | — | Metoprolol, metoprolol plus morphine |
| NCT03275116 The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours. | Chronic Obstructive Airway Disease | P4 | Unknown | 49 | RCT, Open-label | Tiotropium 'Respimat' 5 mcg, Aclidinium Bromide/Formoterol Fumarate 340/12 mcg |
| NCT00206102 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder | Schizophrenia, Schizoaffective Disorder | P4 | Completed | 1,098 | RCT, Open-label | quetiapine fumarate, risperidone |
| NCT00295412 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients | Schizophrenia, Substance Use Disorders | P4 | Completed | — | Open-label | quetiapine (drug) |
| NCT00608712 Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) | Postoperative Bariatric Surgery | P4 | Completed | 140 | Open-label | Esomeprazole |
| NCT00716963 Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen? | Mild Intermittent Asthma | P4 | Completed | 7 | RCT, Double-blind | Fluticasone propionate (Flovent Diskus) 250 mcg, budesonide 400 mcg |
| NCT03181880 To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | P4 | Withdrawn | — | RCT, Open-label | Aclidinium bromide/formoterol fumarate combination, Standard of Care |
| NCT07279935 Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. | Non-small Cell Lung Cancer | P4 | Not Yet Recruiting | 100 | Open-label | Osimertinib+cisplatin or carboplatin + pemetrexed Edit |
| NCT00687310 Does Tailored Education in Asthma Care Help Improve Patient Satisfaction, Adherence, and Quality of Life (TEACH) Trial | Asthma | P4 | Completed | 160 | RCT, Open-label | — |
| NCT02243176 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy | Type 2 Diabetes Mellitus | P4 | Completed | 689 | RCT, Open-label | Saxagliptin, Acarbose |
| NCT00931723 Adult Bipolar Mania | Acute Mania | P4 | Completed | 356 | RCT, Double-blind | Quetiapine fumarate XR, Lithium, Placebo |
| NCT00291408 Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD | Chronic Obstructive Pulmonary Disease (COPD), Age Matched Healthy Volunteers (Non-smokers) | P4 | Withdrawn | — | RCT, Double-blind | — |
| NCT04869124 Dapagliflozin on Volume Vascular Outcomes. | Heart Failure，Congestive | P4 | Completed | 80 | RCT, Double-blind | Dapagliflozin, Placebo |
| NCT00637559 Barrett's Esophagus - 315 - 3 Way Cross-Over | Barrett's Esophagus | P4 | Completed | 50 | RCT, Double-blind | Esomeprazole Magnesium |
| NCT00579280 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD | Bipolar Disorder, Panic Disorder | P4 | Completed | 224 | RCT, Double-blind | quetiapine SR, divalproex sodium ER, placebo |
| NCT00668265 Anxiety in Recovering Opiate Dependence | Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission | P4 | Terminated | 14 | RCT, Double-blind | Quetiapine |
| NCT00427960 Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg | Hypercholesterolaemia | P4 | Terminated | 55 | RCT, Double-blind | rosuvastatin, atorvastatin |
| NCT01128114 Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy | Acute Bipolar Mania | P4 | Terminated | 32 | Open-label | Quetiapine fumarate (Seroquel XR) |
| NCT01224067 Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults | Social Anxiety Disorder | P4 | Completed | 40 | RCT, Double-blind | Quetiapine |
| NCT01170364 Studying the Effects of Sibutramine on Eating Behavior | Obesity | P4 | Terminated | 14 | RCT, Double-blind | Sibutramine, Placebo |
| NCT00779506 Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) | Schizophrenia | P4 | Completed | 96 | Open-label | Quetiapine Fumarate XR |
| NCT00186043 Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II | Bipolar II Disorder | P4 | Completed | 55 | RCT, Double-blind | Quetiapine/Seroquel, Placebo |
| NCT02839889 Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) | Cancer, Constipation | P4 | Terminated | 12 | RCT, Double-blind | Naloxegol, Placebo |
| NCT04363697 Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) | Acute Heart Failure, Heart Failure | P4 | Completed | 2,401 | RCT, Double-blind | Dapagliflozin, Placebo |
| NCT01645735 Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus | Infections | P4 | Completed | 49 | RCT, Double-blind | Ceftaroline fosamil, Ceftriaxone plus vancomycin |
| NCT00574925 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients | Gastroesophageal Reflux Disease (GERD) | P4 | Completed | — | RCT, Double-blind | Esomeprazole |
| NCT00214617 Effect of Crestor on Lipoprotein Metabolism in Humans | Hypercholesterolemia | P4 | Completed | 8 | Open-label | Rosuvastatin at 5 mg/day and 40 mg/day |
| NCT02564926 Foxiga Korea Local Phase 4 Study | Diabetes Mellitus, Type 2 | P4 | Completed | 125 | RCT, Open-label | Dapagliflozin, Glimepiride |
| NCT07430306 A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P3 | Not Yet Recruiting | 245 | Open-label | Anifrolumab |
| NCT00243724 HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease | Gastroesophageal Reflux, Heartburn | P3 | Completed | 350 | RCT, Open-label | Esomeprazole |
| NCT03402841 Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients | Non-Germline BRCA Mutated Ovarian Cancer | P3 | Completed | 279 | Open-label | Olaparib |
| NCT00215254 Quetiapine in Social Anxiety Disorder | Social Anxiety Disorder | P2P3 | Completed | 15 | RCT, Double-blind | quetiapine |
| NCT00326144 Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders | Major Depressive Disorder | P3 | Completed | 310 | RCT, Double-blind | Quetiapine fumarate |
| NCT00240292 Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines | Heart Failure, Congestive | P3 | Completed | 160 | RCT, Double-blind | Rosuvastatin |
| NCT02463071 AZD0585 Phase III Long-term Study in Japan | Hypertriglyceridemia | P3 | Completed | 383 | RCT, Double-blind | AZD0585, AZD0585 placebo |
| NCT00657904 Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer | Non-metastatic Prostate Cancer | P3 | Completed | 3,618 | RCT, Double-blind | Bicalutamide, Placebo |
| NCT00163449 Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207) | Asthma | P3 | Completed | 1,000 | RCT, Double-blind | Ciclesonide, Placebo |
| NCT00044668 Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination | Diabetes Mellitus, Type 2 | P3 | Completed | 155 | Open-label | AC2993 |
| NCT03022097 Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients | COPD | P3 | Completed | 1,625 | RCT, Double-blind | Aclidinium bromide/formoterol Fixed-Dose Combination, Aclidinium bromide, Formoterol Fumarate, Placebo |
| NCT04298229 Efficacy and Safety of Dapagliflozin in Acute Heart Failure | Heart Failure, Diabetes Mellitus, Type 2 | P3 | Completed | 240 | RCT, Single-blind | Dapagliflozin 10 MG |
| NCT00327769 Faslodex Advanced Breast Cancer Local Chinese Study | Advanced Breast Cancer | P3 | Completed | 234 | RCT, Double-blind | Fulvestrant, Anastrozole |
| NCT00163501 Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404) | Perennial Allergic Rhinitis, Allergic Rhinitis | P3 | Completed | 600 | RCT, Double-blind | Ciclesonide |
| NCT00852631 Seroquel XR in Adults With Schizophrenia | Schizophrenia | P3 | Terminated | 28 | Open-label | Quetiapine fumarate (Seroquel) |
| NCT02875834 A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia | Hyperkalemia | P3 | Completed | 267 | RCT, Double-blind | Sodium Zirconium Cyclosilicate (ZS) 10g, Sodium Zirconium Cyclosilicate (ZS) 5g, Sodium Zirconium Cyclosilicate (ZS) 10g, Placebo |
| NCT05573464 A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Completed | 559 | RCT, Double-blind | BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg |
| NCT00357370 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes | Type 2 Diabetes | P2P3 | Completed | 163 | RCT, Double-blind | Dapagliflozin, Placebo |
| NCT00305487 Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417) | Hay Fever, Seasonal Allergic Rhinitis | P3 | Completed | 660 | RCT, Double-blind | Ciclesonide nasal spray |
| NCT02808819 A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist | Asthma | P3 | Completed | 447 | Open-label | Benralizumab, Benralizumab |
| NCT04410198 Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants | Anemia Associated With End Stage Renal Disease (ESRD) | P3 | Completed | 203 | Open-label | Roxadustat |
| NCT00090675 Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer | Non-Small-Cell Lung Carcinoma | P3 | Withdrawn | — | RCT, Double-blind | ZD1839 |
| NCT00528372 A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise | Type 2 Diabetes | P3 | Completed | 1,067 | RCT, Double-blind | Dapagliflozin, Dapagliflozin placebo, Metformin |
| NCT00244595 Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age | Hypertension | P3 | Completed | 235 | Open-label | candsartan cilexetil |
| NCT00646620 Symbicort Onset of Action 1 | Asthma | P3 | Completed | 48 | RCT, Double-blind | budesonide/formoterol (Symbicort), fluticasone/salmeterol (Advair Diskus), albuterol (Ventolin) |
| NCT00122070 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder | Borderline Personality Disorder | P3 | Completed | 15 | Open-label | Quetiapine Fumarate |
| NCT02229383 Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus | Diabetes Mellitus | P3 | Completed | 464 | RCT, Double-blind | Exenatide, Exenatide matching placebo |
| NCT03534453 Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy | P3 | Completed | 229 | Open-label | Olaparib 300mg tablets |
| NCT01434186 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone | Diabetes Mellitus, Type 2 | P3 | Completed | 32 | RCT, Double-blind | Placebo matching with Saxagliptin, Metformin IR, Metformin XR, Saxagliptin |
| NCT00259077 Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population | Non-erosive Reflux Disease | P3 | Completed | 270 | RCT, Double-blind | Omeprazole |
| NCT00357734 Iressa Follow-up Trial | Lung Cancer, Breast Cancer | P3 | Completed | 14 | Open-label | Gefitinib |
| NCT00139165 Long-Term Treatment of Collagenous Colitis With Budesonide | Collagenous Colitis | P3 | Unknown | 36 | RCT, Double-blind | Budesonide |
| NCT03084471 An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. | Advanced Solid Malignancies | P3 | Completed | 867 | Open-label | MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab |
| NCT01730534 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events | Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event | P3 | Completed | 17,190 | RCT, Double-blind | Dapagliflozin 10 mg, Placebo tablet |
| NCT00653965 Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) | Hypercholesterolemia, Dyslipidaemia | P3 | Completed | 3,000 | RCT, Open-label | Rosuvastatin, Atorvastatin |
| NCT01096017 To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study | Asthma | P3 | Completed | 24 | RCT, Single-blind | Terbutaline Turbuhaler®, Salbutamol pMDI |
| NCT02369874 Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer | Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN | P3 | Completed | 736 | RCT, Open-label | MEDI4736, MEDI4736 + Tremelimumab, Standard of Care |
| NCT00108004 Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | P3 | Completed | 400 | Open-label | pramlintide acetate |
| NCT00324363 Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin | Type 2 Diabetes Mellitus | P3 | Completed | 466 | RCT, Double-blind | exenatide, Placebo |
| NCT00228514 Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study | Rosuvastatin, Heart Failure | P3 | Completed | 40 | RCT, Double-blind | Rosuvastatin |
| NCT01606007 Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes | Type 2 Diabetes | P3 | Completed | 1,282 | RCT, Double-blind | Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin |
| NCT01294423 Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes, High Blood Sugar | P3 | Completed | 261 | RCT, Double-blind | Dapagliflozin, Dapagliflozin, Placebo |
| NCT00241540 Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs | GERD | P3 | Completed | 808 | RCT, Double-blind | Esomeprazole |
| NCT00388973 Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder | Major Depressive Disorder | P3 | Completed | 338 | RCT, Double-blind | Quetiapine |
| NCT00457899 Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder | Schizophrenia, Schizoaffective Disorders | P3 | Terminated | 234 | RCT, Open-label | Quetiapine IR (Immediate Release) |
| NCT00379249 Rosuvastatin ORBITAL Germany | Hypercholesterolemia | P3 | Completed | 8,000 | RCT, Open-label | Rosuvastatin |
| NCT00577824 Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) | Type 2 Diabetes | P3 | Completed | 181 | RCT, Double-blind | exenatide, exenatide, placebo |
| NCT02454933 Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours | Locally Advanced or Metastatic EGFR T790M+ NSCLC | P3 | Completed | 29 | RCT, Open-label | AZD9291, MEDI4736 |
| NCT02326285 Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB | Non-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA | P2P3 | Terminated | 1 | Open-label | Gefitinib, docetaxel, cisplatin |
| NCT00196859 Study in Elderly Patients With Early Breast Cancer (ICE) | Breast Cancer | P3 | Completed | 1,500 | RCT, Open-label | Ibandronate, Capecitabine, Ibandronate |
| NCT01197508 A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder. | Major Depressive Disorder | P3 | Completed | 696 | RCT, Double-blind | TC-5214, Placebo |
| NCT00811473 Pediatric Bipolar Depression | Bipolar Depression | P3 | Completed | 193 | RCT, Double-blind | Quetiapine XR, Placebo |
| NCT00641680 Rhinocort Aqua Versus Placebo and Fluticasone Propionate | Seasonal Allergic Rhinitis | P3 | Completed | 750 | RCT, Double-blind | Budesonide, Fluticasone propionate, Placebo |
| NCT03347279 Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma | Asthma | P3 | Completed | 1,061 | RCT, Double-blind | Experimental: Tezepelumab |
| NCT00673231 Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin | Type 2 Diabetes | P3 | Completed | 1,240 | RCT, Double-blind | Dapagliflozin, Dapagliflozin, Dapagliflozin, Placebo, Dapagliflozin, Dapagliflozin |
| NCT00302770 Efficacy of Quetiapine in Generalised Social Anxiety Disorder | Social Anxiety Disorder | P3 | Terminated | 50 | RCT, Double-blind | quetiapine |
| NCT03354429 THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death | Acute Ischaemic Stroke, Transient Ischaemic Attack | P3 | Completed | 11,016 | RCT, Double-blind | Ticagrelor, Placebo |
| NCT03170271 A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. | Asthma | P3 | Completed | 660 | RCT, Double-blind | Benralizumab (Medi-563), Placebo |
| NCT01003184 Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 222 | RCT, Open-label | exenatide once weekly, insulin detemir |
| NCT00076076 The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023) | Asthma | P3 | Completed | 822 | RCT, Double-blind | Roflumilast |
| NCT00500318 A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Pulmonary Disease, Chronic Obstructive | P3 | Completed | 181 | RCT, Double-blind | Aclidinium Bromide, Placebo |
| NCT06034743 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension | Uncontrolled Hypertension, Resistant Hypertension | P3 | Completed | 796 | RCT, Double-blind | Baxdrostat, Placebo |
| NCT01572792 Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | P3 | Completed | 921 | RCT, Double-blind | Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate, Placebo |
| NCT00984867 Dapagliflozin DPPIV Inhibitor add-on Study | Type 2 Diabetes | P3 | Completed | 833 | RCT, Double-blind | Dapagliflozin, Placebo |
| NCT00241514 Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs | GERD | P3 | Completed | 334 | RCT, Double-blind | Esomeprazole |
| NCT02104817 Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia | Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD) | P3 | Completed | 13,078 | RCT, Double-blind | Epanova® (omega-3 carboxylic acids), corn oil control |
| NCT04612790 A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. | Bullous Pemphigoid | P3 | Terminated | 67 | RCT, Double-blind | Benralizumab, Placebo |
| NCT04518410 ACTIV-2: A Study for Outpatients With COVID-19 | Coronavirus, Covid19 | P2P3 | Completed | 4,044 | RCT, Double-blind | bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg |
| NCT03263091 Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden | Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia | P3 | Terminated | 184 | RCT, Double-blind | Roxadustat, Placebo |
| NCT02052310 Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants | Anemia in Incident Dialysis Patients | P3 | Completed | 1,043 | RCT, Open-label | Roxadustat, Epoetin Alfa |
| NCT00626535 A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD) | Symptomatic Gastroesophageal Reflux Disease (sGERD) | P3 | Completed | 500 | RCT, Double-blind | Esomeprazole, Matching placebo |
| NCT01924533 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | Gastric Cancer | P3 | Completed | 525 | RCT, Double-blind | Olaparib, Paclitaxel, Placebo |
| NCT00642161 New Version Pulmicort Turbuhaler USA Children | Asthma | P3 | Completed | 430 | RCT, Double-blind | budesonide |
| NCT01838499 Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Terminated | 224 | RCT, Double-blind | MEDI8968, Saline |
| NCT00206492 Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | Breast Cancer | P2 | Terminated | 3 | Open-label | Iressa, Tamoxifen |
| NCT00872716 Quetiapine in Specific Phobia | Specific Phobia | P2 | Completed | 60 | RCT, Double-blind | Quetiapine XR |
| NCT00372944 AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy | Pancreatic Cancer | P2 | Completed | 70 | RCT, Open-label | AZD6244, capecitabine |
| NCT00048087 Iressa/Docetaxel in Non-Small-Cell Lung Cancer | Non-small Cell Lung Cancer | P2 | Withdrawn | — | Open-label | ZD1839, Docetaxel |
| NCT00951132 Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy | Depression | P2 | Withdrawn | — | RCT, Double-blind | rosuvastatin, Placebo |
| NCT02866747 A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma | Glioblastoma | P1P2 | Completed | 108 | RCT, Open-label | Durvalumab |
| NCT00242918 Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer | Prostate Cancer | P2 | Completed | 29 | Open-label | docetaxel, ZD1839 |
| NCT07175415 HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | P1P2 | Not Yet Recruiting | 42 | Open-label | Capivasertib, Venetoclax, Intrathecal chemotherapy |
| NCT06579092 Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity | Obesity or Overweight | P2 | Completed | 310 | RCT, Double-blind | AZD5004, Placebo |
| NCT05267392 Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy | Non-small Cell Lung Cancer | P1P2 | Unknown | 30 | Open-label | Durvalumab |
| NCT01005251 Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI | Gastroesophageal Reflux Disease, Heartburn | P2 | Completed | 661 | RCT, Double-blind | lesogaberan (AZD3355), lesogaberan (AZD3355), lesogaberan (AZD3355), lesogaberan (AZD3355), Placebo |
| NCT02388295 AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients | Multiple System Atrophy, MSA | P2 | Completed | 59 | RCT, Double-blind | AZD3241, Placebo |
| NCT04760730 Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) | COVID-19 | P1P2 | Completed | 100 | RCT, Single-blind | AZD1222, rAd26-S |
| NCT06634056 Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation | Non-Small Cell Lung Cancer, Radiation Induced Lung Injury (RILI) | P2 | Not Yet Recruiting | 150 | RCT, Double-blind | Pentoxifylline |
| NCT00183963 A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) | Breast Carcinoma | P2 | Terminated | 4 | RCT, Open-label | Tamoxifen, Fulvestrant, Fulvestrant |
| NCT00322348 Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women | Advanced Breast Cancer | P2 | Completed | 98 | RCT, Open-label | Goserelin acetate, Goserelin acetate |
| NCT02318277 A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | Solid Tumors, Head and Neck Cancer | P1P2 | Completed | 176 | Open-label | MEDI4736, INCB024360 |
| NCT04231864 Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma | P2 | Withdrawn | — | Open-label | Durvalumab, Epacadostat |
| NCT02628132 Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients | Breast Cancer | P1P2 | Completed | 22 | Open-label | Paclitaxel, Durvalumab |
| NCT02077569 AKT Inhibitor in Oestrogen Positive Breast Cancer | Invasive Breast Cancer | P2 | Completed | 48 | RCT, Double-blind | AZD5363 |
| NCT04686773 Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention | COVID-19 | P2 | Completed | 100 | Open-label | AZD1222, rAd26-S |
| NCT02070653 The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion | Abdominal Aortic Aneurysm | P2 | Completed | 145 | RCT, Double-blind | Ticagrelor, Placebo |
| NCT03234153 Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin | Muscle-invasive Bladder Cancer | P2 | Terminated | 6 | Open-label | Durvalumab (Imfinzi), Tremelimumab |
| NCT01145560 A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock | Severe Sepsis, Septic Shock | P2 | Completed | 300 | RCT, Double-blind | AZD9773, Placebo |
| NCT00233623 Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Withdrawn | 190 | RCT, Open-label | Iressa (Gefitinib), Irinotecan, 5Fluorouracil, Leucovorin |
| NCT03809663 A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis | Atopic Dermatitis | P2 | Terminated | 251 | RCT, Double-blind | Tezepelumab |
| NCT06692764 A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure | Atherosclerotic Cardiovascular Disease | P2 | Completed | 202 | RCT, Double-blind | Placebo, AZD0780 |
| NCT00264498 Phase II Iressa & Carbo/Gem in NSCLC | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 38 | RCT, Open-label | Gefitinib, Gemcitabine, Carboplatin |
| NCT01530334 Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment | Lung Cancer | P2 | Completed | 61 | Open-label | Gefitinib 250mg |
| NCT00282178 Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo | Hypertension, Obesity | P2 | Completed | 26 | RCT, Double-blind | Hydrochlorothiazide, Placebo, Candesartan |
| NCT04810104 Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug | Parkinson Disease, Mild Cognitive Impairment | P2 | Withdrawn | — | RCT, Double-blind | AZD0328, Placebo |
| NCT04301778 Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic Cholangiocarcinoma | P2 | Completed | 5 | Open-label | Durvalumab, SNDX-6352 |
| NCT06595238 A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity | Obesity or Overweight | P2 | Completed | 262 | RCT, Double-blind | AZD6234, Placebo comparator |
| NCT03106155 Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification | Small Cell Lung Cancer | P2 | Terminated | 4 | Open-label | vistusertib (AZD2014) |
| NCT01823068 Vandetanib in Advanced NSCLC With RET Rearrangement | Non Small Cell Lung Cancer | P2 | Completed | 17 | Open-label | Vandetanib |
| NCT05737940 A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 | Pulmonary Hypertension (World Health Organization Group 2), Heart Failure | P2 | Completed | 260 | RCT, Double-blind | AZD3427, Placebo |
| NCT02901548 Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | Carcinoma in Situ of Bladder, Bladder Cancer | P2 | Terminated | 17 | Open-label | Durvalumab |
| NCT00743444 TLESR-impedance Study in Patients | Reflux Episodes | P2 | Completed | 27 | RCT, Double-blind | AZD3355, Placebo |
| NCT01048333 Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler® | Chronic Obstructive Pulmonary Disease | P2 | Completed | 109 | RCT, Double-blind | Formoterol, Salmeterol, Placebo |
| NCT01482221 A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder | Major Depressive Disorder | P2 | Completed | 542 | RCT, Double-blind | AZD6765 iv, AZD6765 iv, Placebo |
| NCT00757692 Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. | Prostate Cancer | P2 | Completed | 74 | RCT, Open-label | Vandetanib, Bicalutamide |
| NCT00090363 ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA) | Prostate Cancer | P2 | Completed | 447 | RCT, Double-blind | ZD4054 15 mg, Placebo, ZD4054 10 mg |
| NCT00976534 Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain | Pain, Neuropathic Pain | P2 | Terminated | 90 | RCT, Double-blind | AZD1386, Placebo |
| NCT01837823 YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering | Obstructive Coronary Artery Disease, Coronary Artery Disease | P2 | Completed | 91 | Open-label | rosuvastatin |
| NCT04336943 Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load | Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma | P2 | Terminated | 6 | Open-label | Durvalumab, Olaparib |
| NCT00278889 Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | Colorectal Cancer | P2 | Completed | 215 | RCT, Double-blind | AZD2171, 5-fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab |
| NCT04630756 AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer | Advanced Haematological Malignancies | P1P2 | Completed | 40 | Open-label | AZD4573, Acalabrutinib |
| NCT01625286 Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients | Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer | P1P2 | Completed | 148 | RCT, Double-blind | AZD5363 when combined with weekly paclitaxel., AZD5363 when combined with weekly paclitaxel., AZD5363when combined with weekly paclitaxel., A placebo in combination with weekly paclitaxel. |
| NCT00558272 Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease | Breast Cancer, Prostate Cancer | P2 | Completed | 139 | RCT, Open-label | AZD0530, Zoledronic Acid |
| NCT00402896 Malignant Pleural Effusion With ZD6474 | Lung Cancer, Pleural Effusion | P2 | Terminated | 28 | Open-label | ZD6474 |
| NCT02803203 Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers | P1P2 | Completed | 49 | Open-label | osimertinib, Bevacizumab |
| NCT00781742 AZD6765 Severe Major Depressive Disorder (MDD) IV | Major Depressive Disorder | P2 | Completed | 152 | RCT, Double-blind | AZD6765, Placebo |
| NCT00856908 Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes | Type II Diabetes | P2 | Completed | 20 | RCT, Single-blind | AZD1656, Placebo |
| NCT03473574 Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients | Cholangiocarcinoma, Gall Bladder Carcinoma | P2 | Completed | 128 | RCT, Open-label | Durvalumab, Gemcitabine, Cisplatin, Tremelimumab |
| NCT00410189 BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | Lung Cancer | P2 | Completed | 54 | Open-label | ZD6474 |
| NCT04039113 Tezepelumab COPD Exacerbation Study | Chronic Obstructive Pulmonary Disease (COPD) | P2 | Completed | 337 | RCT, Double-blind | Tezepelumab |
| NCT01802632 AZD9291 First Time In Patients Ascending Dose Study | Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer | P1P2 | Completed | 603 | Open-label | AZD9291 |
| NCT00193336 Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer | Lung Cancer | P2 | Completed | 60 | Open-label | ZD1839 |
| NCT03732352 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma | EGFR Gene Amplification, EGFR Gene Mutation | P2 | Completed | 12 | Open-label | Osimertinib |
| NCT03865511 MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib | Non-small Cell Lung Cancer | P2 | Unknown | 150 | Open-label | TAGRISSO® 80mg (Osimertinib) |
| NCT01499303 Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer | Diffuse Large B-Cell Lymphoma | P2 | Completed | 101 | Open-label | Fostamatinib |
| NCT00641979 New Nasal Applicator / New Formulation - User Study | Seasonal Allergic Rhinitis | P2 | Completed | 200 | RCT, Double-blind | budesonide, Placebo |
| NCT02031679 Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines | Chronic Idiopathic Urticaria | P2 | Completed | 38 | RCT, Double-blind | AZD1981, Placebo |
| NCT05251259 Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma | Asthma | P2 | Completed | 670 | RCT, Double-blind | Atuliflapon, Placebo |
| NCT02938793 Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors | Cancer, Rare Disease | P2 | Terminated | 92 | Open-label | Durvalumab, Tremelimumab |
| NCT00423332 Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma | Renal Cell Carcinoma | P2 | Completed | 105 | RCT, Double-blind | Cediranib, Cediranib Placebo |
| NCT04643158 Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids | Asthma | P2 | Terminated | 72 | RCT, Double-blind | AZD1402, Placebo, Short acting beta agonist (SABA) (rescue medication), Run-in medications (ICS-LABA combination) |
| NCT02328014 Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | Non-Hodgkins Lymphoma, Multiple Myeloma | P1P2 | Completed | 40 | Open-label | Acalabrutinib, ACP-319 |
| NCT00099333 Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents | Type 2 Diabetes Mellitus | P2 | Completed | 49 | RCT, Open-label | exenatide, Insulin |
| NCT00785408 Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects | Obesity, Overweight | P2 | Completed | 273 | RCT, Double-blind | AC2307, placebo, AC2307, placebo, AC2307, placebo |
| NCT06350123 Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease | Chronic Kidney Disease | P2 | Completed | 324 | RCT, Double-blind | Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin |
| NCT01049360 Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo | Chronic Obstructive Pulmonary Disease | P2 | Completed | 128 | RCT, Double-blind | Aclidinium 400 μg / Formoterol 12 μg, Aclidinium 400 μg / Formoterol 6 μg, Aclidinium 400 μg, Formoterol 12 μg, Placebo |
| NCT01310855 Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma | Glioblastoma | P2 | Terminated | 38 | RCT, Double-blind | cediranib maleate, gefitinib, Placebo |
| NCT03557918 Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | Urothelial Carcinoma | P2 | Completed | 26 | Open-label | Tremelimumab |
| NCT01902290 Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility | Asthma | P2 | Terminated | 421 | RCT, Double-blind | Placebo, Brodalumab |
| NCT05038904 Preventing Anaphylaxis With Acalabrutinib | Food Allergy, Food Allergy Peanut | P2 | Completed | 10 | Open-label | Acalabrutinib |
| NCT04364048 Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | Lung Cancer, Non-small Cell Carcinoma | P2 | Terminated | 10 | Open-label | Induction Durvalumab, Chemotherapy, Consolidation durvalumab |
| NCT00733668 Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder | Major Depressive Disorder | P2 | Completed | — | Open-label | Quetiapine fumarate (Seroquel) |
| NCT01348139 Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma | Asthma | P2 | Completed | 39 | RCT, Double-blind | AZD3199, AZD3199 |
| NCT01666613 A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways | Healthy | P1 | Withdrawn | — | RCT, Open-label | AZD8683, AZD8683, AZD8683, AZD8683 |
| NCT02653872 A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects | Healthy Subjects | P1 | Completed | 15 | Open-label | AZD7986, Verapamil, Itraconazole, Diltiazem |
| NCT00704366 AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours | Solid Tumor | P1 | Completed | 18 | Open-label | AZD0530 |
| NCT01311622 Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects | Rheumatoid Arthritis, Healthy Subjects | P1 | Completed | 15 | Open-label | warfarin, fostamatinib |
| NCT01392807 Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function | Hepatic; Functional Disturbance | P1 | Completed | 24 | Open-label | NKTR-118 |
| NCT01755494 A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration | Type 2 Diabetes Mellitus(T2DM) | P1 | Completed | 64 | RCT, Open-label | Saxagliptin 5 mg, Metformin XR 500 mg, Mertformin XR 2 x 500 mg, Komboglyze XR 5/500 mg, Komboglyze XR 5/1000 mg |
| NCT01533155 Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118 | Drug Induced Constipation | P1 | Completed | 214 | RCT, Double-blind | Nektar 118, Quinidine, Quinidine placebo, Morphine |
| NCT02963116 A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet | High Risk Coronary Artery Disease | P1 | Completed | 12 | RCT, Open-label | AZD5718 IR tablet, AZD5718 oral suspension, Rosuvastatin tablet |
| NCT00502164 Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer | Advanced Prostate Adenocarcinoma | P1 | Completed | 40 | Open-label | AZD2171 |
| NCT04630067 Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 | Heart Failure | P1 | Completed | 105 | RCT, Double-blind | AZD3427, Placebo |
| NCT06554821 A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants | Healthy Participants | P1 | Completed | 28 | RCT, Open-label | Rosuvastatin, Ticagrelor |
| NCT06348355 A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 7 | Open-label | [11C]savolitinib, Savolitinib |
| NCT00502385 Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML | Leukaemia, Myelocytic | P1 | Completed | 54 | Open-label | AZD2171 |
| NCT00766025 Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin | CYP2C19 Poor, Extensive Metabolizers | P1 | Completed | 50 | Open-label | Rosuvastatin Calcium |
| NCT00750425 Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours | Advanced Solid Tumors | P1 | Completed | 46 | Open-label | cediranib (RECENTIN TM, AZD2171) |
| NCT01095991 Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P1 | Completed | 12 | RCT, Open-label | AZD1656, Sitagliptin |
| NCT00782574 Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients | Advanced Solid Tumors | P1 | Completed | 57 | Open-label | AZD2281, Cisplatin |
| NCT00960349 Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients | Gastric Cancer | P1 | Completed | 14 | Open-label | Cediranib, Cisplatin, S-1, Cisplatin, Capecitabine |
| NCT03430518 Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer | P1 | Completed | 9 | Open-label | Durvalumab, Eribulin |
| NCT03669601 AZD6738 & Gemcitabine as Combination Therapy | Cancer | P1 | Unknown | 55 | RCT, Open-label | AZD6738, Gemcitabine |
| NCT00713765 Pharmacokinetic Interaction Between AZD3480 and Donepezil | Alzheimer's Disease | P1 | Terminated | 33 | RCT, Double-blind | AZD3480, Donepezil |
| NCT01171105 Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects | Healthy | P1 | Completed | 73 | RCT, Double-blind | AZD5213, Placebo to AZD5213 |
| NCT02617277 Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | Advanced Solid Tumours | P1 | Completed | 56 | Open-label | AZD1775, MEDI4736 |
| NCT03381183 IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck | P1 | Completed | 19 | Open-label | Durvalumab, IRX-2 Regimen |
| NCT03263637 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia | P1 | Completed | 44 | Open-label | AZD4573 |
| NCT00757419 AZD3355 Dose-escalation Study in Healthy Males | Reflux Disease | P1 | Completed | 54 | RCT, Single-blind | AZD3355, Placebo |
| NCT04734275 Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers | Chronic Kidney Disease | P1 | Completed | 16 | RCT, Open-label | AZD5718 |
| NCT00817505 To Evaluate the Bioavailability of a Tablet of AZD1656 | Type 1 Diabetes | P1 | Completed | 11 | RCT, Open-label | AZD1656, AZD1656 |
| NCT07511205 A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity | Healthy Participants, Obesity | P1 | Not Yet Recruiting | 112 | RCT, Double-blind | AZD1043 |
| NCT03804645 A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects | Heart Failure | P1 | Completed | 12 | RCT, Open-label | Treatment A, Treatment B, Treatment C, Treatment D |
| NCT00729495 Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib | Healthy Volunteer | P1 | Completed | 80 | RCT, Open-label | celecoxib |
| NCT00930306 AZD2066 Cocktail Study | Chronic Pain | P1 | Completed | 15 | RCT, Open-label | AZD2066, Caffeine, Tolbutamide, Omeprazole Tablet, 20 mg, Midazolam Tablet, 7.5 mg |
| NCT02737059 Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects | Constipation Drug Induced | P1 | Completed | 72 | RCT, Double-blind | Naloxegol, Codeine, codeine placebo, naloxegol placebo |
| NCT02059434 Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD | Chronic Obstructive Pulmonary Disease (COPD), Asthma | P1 | Completed | 55 | RCT, Single-blind | LAS190792 Dose 1, LAS190792 Dose 2, LAS190792 Dose 3, LAS190792 Dose 4, LAS190792 Dose 5, LAS190792 Dose 6, LAS190792 Dose 1 (Part 2), LAS190792 Dose 2 (Part 2), Tiotropium 18 μg, Indacaterol 150 μg, Placebo |
| NCT03836599 A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects | Chronic Kidney Disease | P1 | Completed | 6 | RCT, Double-blind | Verinurad, Allopurinol, Placebo |
| NCT02430311 The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. | Advanced Solid Tumours | P1 | Completed | 36 | Open-label | Olaparib, Paclitaxel, Olaparib |
| NCT01094093 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis | Psoriasis | P1 | Completed | 73 | RCT, Double-blind | AMG 139 |
| NCT00503412 Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors | Advanced Solid Metastatic Tumor | P1 | Completed | 6 | Open-label | AZD2171 |
| NCT00970775 AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects | Healthy Volunteer | P1 | Completed | 32 | RCT, Double-blind | AZD2423, Placebo |
| NCT04769869 A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma | Asthma | P1 | Completed | 110 | RCT, Single-blind | AZD4604 for inhalation via DPI, Placebo for AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration, AZD4604 for inhalation via DPI |
| NCT00535353 AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer | Colorectal Cancer | P1 | Completed | 26 | Open-label | irinotecan hydrochloride, olaparib |
| NCT05033431 Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants | Healthy Participants | P1 | Completed | 48 | Open-label | Brazikumab |
| NCT06599502 A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation | Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC) | P1 | Terminated | 17 | Open-label | AZD0022, Cetuximab |
| NCT06925854 A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants | Healthy | P1 | Completed | 12 | RCT, Open-label | AZD4144, Rosuvastatin |
| NCT03492931 PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4) | Sickle Cell Disease | P1 | Completed | 21 | Open-label | Ticagrelor |
| NCT01146756 MEK Inhibitor and Thoracic Radiotherapy Trial | Non Small Cell Lung Cancer | P1 | Completed | 21 | Open-label | AZD6244 |
| NCT01884285 AZD8186 First Time In Patient Ascending Dose Study | Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC | P1 | Completed | 147 | Open-label | Part A: AZD8186 monotherapy, Part B: AZD8186 monotherapy, Part C1: Abiraterone acetate combination with AZD8186, Part D1: AZD2014 combination with AZD8186, Part D2 AZD2014 combination with AZD8186, Part C2: Abiraterone acetate combination with AZD8186 |
| NCT02906059 Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P1 | Completed | 7 | Open-label | AZD1775, Irinotecan |
| NCT02601625 A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects | Safety, Pharmacokinetics | P1 | Completed | 30 | RCT, Double-blind | Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg), Anifrolumab placebo SC injection (300mg), Anifrolumab placebo IV infusion (300mg), Anifrolumab placebo SC infusion (600mg) |
| NCT06662123 Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 24 | RCT, Open-label | Anifrolumab |
| NCT00314782 Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC | Prostate Cancer | P1 | Completed | 44 | RCT, Double-blind | ZD4054 (Zibotentan), Docetaxel, Placebo |
| NCT03315091 Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours | Solid Tumours | P1 | Completed | 31 | RCT, Open-label | Treatment A - AZD1775 administered under fasted conditions, Treatment B - AZD1775 administered under fed conditions. |
| NCT00713791 Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets. | Healthy | P1 | Completed | 20 | RCT, Single-blind | ZD4054, ZD4054, ZD4054, ZD4054 |
| NCT04712396 A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body | Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) | P1 | Completed | 11 | Open-label | Capivasertib, Itraconazole |
| NCT04600505 A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol | Chronic Obstructive Pulmonary Disease (COPD) | P1 | Completed | 47 | RCT, Single-blind | Treatment A, Treatment B, Treatment C |
| NCT00722956 Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin | Healthy Volunteers, Pharmacokinetics | P1 | Completed | 12 | Open-label | AZD5672, atorvastatin |
| NCT07391670 A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab | Solid Tumours | P1 | Not Yet Recruiting | 40 | RCT, Open-label | SC durvalumab + rHu, IV durvalumab, Tremelimumab |
| NCT00700986 Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056 | Rheumatoid Arthritis | P1 | Completed | 12 | RCT, Double-blind | AZD9056, Placebo |
| NCT00515866 Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer | Pancreatic Neoplasms | P1 | Completed | 68 | RCT, Open-label | KU-0059436 (AZD2281)(PARP inhibitor), Gemcitabine |
| NCT02679729 To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration | Cystic Fibrosis | P1 | Completed | 63 | RCT, Single-blind | AZD5634 for inhalation, AZD5634 for infusion |
| NCT00824057 Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2) | Healthy | P1 | Completed | 24 | RCT, Double-blind | AZD6280, Midazolam, Caffeine |
| NCT00817271 To Evaluate the Response to Glucagon During Hypoglycemia | Type 2 Diabetes | P1 | Completed | 8 | RCT, Open-label | AZD1656, Glucagon |
| NCT00690287 A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients | Type 2 Diabetes | P1 | Completed | 24 | RCT, Single-blind | AZD6370, AZD6370, Placebo |
| NCT01795339 A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients | Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients | P1 | Completed | 47 | RCT, Double-blind | AZD3293, Placebo |
| NCT02249936 A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations | Healthy | P1 | Completed | 18 | RCT, Double-blind | AZD1722, Omeprazole |
| NCT01175564 To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects | Healthy | P1 | Completed | 48 | RCT, Double-blind | TC-5214, Placebo |
| NCT01240148 Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers | Peripheral Neuropathic Pain, Nociceptive Pain | P1 | Completed | 26 | RCT, Double-blind | AZD3161, Lidocaine, AZD3161 Placebo |
| NCT02640755 Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase | Solid Malignancies | P1 | Completed | 4 | Open-label | [14C]AZD2014, Multiple dose AZD2014, Fulvestrant, Paclitaxel |
| NCT04949438 A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers | Renal Impairment | P1 | Completed | 20 | Open-label | AZD4831 |
| NCT03955640 Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences | Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma | P1 | Terminated | 3 | Open-label | Olaparib |
| NCT04742036 Capivasertib China PK Study | Advanced Solid Tumours | P1 | Completed | 16 | Open-label | Capivasertib, Paclitaxel |
| NCT01240967 To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function | Healthy Volunteers, Patients | P1 | Completed | 40 | Open-label | TC-5214 |
| NCT01913028 A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects | Healthy | P1 | Completed | 64 | RCT, Single-blind | MEDI9929, Placebo |
| NCT02372344 A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects | Healthy | P1 | Completed | 72 | RCT, Open-label | AZD0585 |
| NCT02967159 A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants | Chronic Obstructive Pulmonary Disease (COPD), Asthma | P1 | Completed | 14 | RCT, Open-label | Abediterol, AZD7594, AZD7594/abediterol, AZD7594 and abediterol |
| NCT06502379 A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants | Healthy Participants | P1 | Completed | 147 | RCT, Double-blind | AZD8965 |
| NCT05751759 Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment | Hepatic Impairment | P1 | Completed | 31 | Open-label | Mitiperstat |
| NCT03057145 Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors | Solid Tumor | P1 | Completed | 29 | Open-label | Prexasertib, Olaparib |
| NCT00887770 A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart | Rheumatoid Arthritis | P1 | Completed | 64 | RCT, Double-blind | AZD5672, Moxifloxacin, placebo, AZD5672, placebo, placebo |
| NCT00736788 Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers | Healthy Volunteers | P1 | Terminated | 16 | RCT, Double-blind | AZD1704, Placebo |
| NCT00963183 AZD5423 Single Ascending Dose Study | Healthy Volunteers | P1 | Completed | 72 | RCT, Double-blind | AZD5423, Placebo |
| NCT03740373 A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate | Pulmonary Disease, Chronic Obstructive | P1 | Completed | 10 | RCT, Open-label | BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold, BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold |
| NCT04959266 A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib | Advanced Solid Tumours | P1 | Terminated | 5 | Open-label | Adavosertib, Itraconazole, Rifampicin, Omeprazole |
| NCT00972049 Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects | Healthy | P1 | Completed | 40 | RCT, Double-blind | AZD2516, Placebo |
| NCT01055691 A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets | Healthy Volunteers | P1 | Completed | 120 | RCT, Open-label | Dapagliflozin/Metformin, Dapagliflozin, Metformin, Dapagliflozin/Metformin, Dapagliflozin, Metformin |
| NCT01415791 Oral Mucosal Absorption of ICI176,334-1 | Healthy | P1 | Completed | 8 | Open-label | ICI176,334-1 |
| NCT03843060 A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers | Heart Failure With Preserved Ejection Fraction (HFpEF) | P1 | Completed | 14 | Open-label | AZD9977, Itraconazole |
| NCT03463525 Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases | Non-small Cell Lung Cancer | P1 | Completed | 4 | Open-label | Osimertinib, [11C]osimertinib |
| NCT01348724 Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118 | Healthy Volunteers | P1 | Completed | 6 | Open-label | [14C] NKTR-118 |
| NCT03333824 Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer | Solid Tumours | P1 | Completed | 33 | Open-label | CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775 |
| NCT02040064 Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients | Non Small Cell Lung Cancer | P1 | Completed | 27 | Open-label | Gefitinib, Tremelimumab |
| NCT00918398 AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations | Healthy, Postmenopausal | P1 | Completed | 14 | RCT, Open-label | AZD1981, AZD1981, AZD1981, AZD1981 |
| NCT02400333 Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet | Bioavailability, Healthy Subjects | P1 | Completed | 100 | RCT, Open-label | Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water, Ticagrelor OD tablet (90 mg single dose) administered without water, Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube, Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water |
| NCT03022409 A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). | Head and Neck Squamous Cell Carcinoma | P1 | Completed | 21 | RCT, Open-label | Ceralasertib, Olaparib |
| NCT04179071 A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine | Solid Tumours | P1 | Completed | 16 | RCT, Open-label | Savolitinib, Famotidine |
| NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | P1 | Completed | 85 | Open-label | Ramucirumab, MEDI4736 |
| NCT05587998 A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users. | Opioid Use Disorder | P1 | Completed | 45 | RCT, Double-blind | Morphine, AZD4041 |
| NCT01207089 To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329 | Overweight, Healthy | P1 | Completed | 45 | RCT, Single-blind | AZD8329, Placebo |
| NCT01093040 A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects | Healthy | P1 | Completed | 30 | RCT, Single-blind | CAT-354, CAT-354, CAT 354 |
| NCT01359618 Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart | Healthy Male | P1 | Terminated | 16 | RCT, Double-blind | TC-5214, Moxifloxacin |
| NCT06754761 Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib | Neoplasm | P1 | Not Yet Recruiting | 8 | Open-label | [14C] AZD6738, AZD6738 / ceralasertib |
| NCT00692042 Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704 | Pain | P1 | Completed | 80 | RCT, Double-blind | AZD1704 |
| NCT04944771 Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants | Solid and Hematological Malignancies | P1 | Completed | 48 | RCT, Open-label | Capivasertib, Rabeprazole |
| NCT00935025 AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects | Healthy | P1 | Terminated | 45 | RCT, Single-blind | AZD1305, Placebo |
| NCT01525225 Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM | Type 2 Diabetes Mellitus | P1 | Terminated | 4 | Open-label | Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR |
| NCT05512806 A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers | Healthy Participants | P1 | Completed | 16 | RCT, Open-label | AZD5462 |
| NCT00918515 Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD3043 | Healthy | P1 | Completed | 53 | RCT, Open-label | AZD3043 |
| NCT06703658 A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus | Healthy Participants, Type 2 Diabetes | P1 | Completed | 35 | RCT, Double-blind | AZD5004(Part A), Placebo(Part A), AZD5004(Part B), Placebo(Part B) |
| NCT01938612 A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours | Advanced Solid Tumors | P1 | Completed | 269 | Open-label | MEDI4736, tremelimumab |
| NCT01205867 Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects | Butyrylcholinesterase Deficiency | P1 | Completed | 22 | Open-label | AZD8848 |
| NCT00681967 Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer | Head and Neck Cancer | P1 | Completed | 30 | Open-label | Gefitinib, Gefitinib |
| NCT01937338 Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge | LPS Challenge, Neutrophils | P1 | Completed | 60 | RCT, Double-blind | AZD7624, Placebo |
| NCT02586987 A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours | Lung Cancer, Melanoma | P1 | Completed | 58 | Open-label | Selumetinib, MEDI4736, Tremelimumab |
| NCT01331993 A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation | Healthy Volunteers, Bioequivalence | P1 | Completed | 36 | RCT, Open-label | VIMOVO (AstraZeneca), VIMOVO (Patheon), Marketed enteric-coated naproxen formulation |
| NCT02568397 A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants | Healthy | P1 | Completed | 60 | Open-label | Lanabecestat, Dabigatran etexilate |
| NCT04840849 Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults | Evaluate PK Profile | P1 | Completed | 24 | RCT, Double-blind | nirsevimab |
| NCT04483947 A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients | Non-alcoholic Steatohepatitis (NASH) | P1 | Completed | 74 | RCT, Double-blind | AZD2693 |
| NCT03682497 Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium | Heart Failure | P1 | Terminated | 68 | RCT, Open-label | AZD9977, Spironolactone |
| NCT03258515 A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers | Solid Tumors | P1 | Completed | 45 | RCT, Double-blind | AZD6094 200 mg, Moxifloxacin |
| NCT01068717 Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants | Type 2 Diabetes Mellitus | P1 | Completed | 27 | RCT, Open-label | Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state) |
| NCT02248090 AZD9496 First Time in Patients Ascending Dose Study | ER+ HER2- Advanced Breast Cancer | P1 | Completed | 45 | Open-label | AZD9496, AZD9496 |
| NCT00684190 Drug Interaction Study Between AZD3355 and Nexium | Gastroesophageal Reflux Disease | P1 | Completed | 30 | RCT, Open-label | AZD3355, Esomeprazole |
| NCT03205176 AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | Malignant Solid Tumors, Lymphoma | P1 | Completed | 49 | Open-label | AZD5153, Olaparib |
| NCT01283984 AZD2115 Single Ascending Dose Study | Chronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways | P1 | Completed | 96 | RCT, Double-blind | AZD2115, Placebo |
| NCT03085225 Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. | Ovarian Carcinoma, Soft Tissue Sarcoma | P1 | Completed | 40 | Open-label | Combination of trabectedin with durvalumab |
| NCT04488016 A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects | Bioavailability, B-cell Lymphoid Cancer | P1 | Completed | 54 | RCT, Open-label | Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2 |
| NCT00474019 Phase 1 Pharmacokinetics of Intravenous Nexium in Children | Pharmacokinetics | P1 | Completed | 42 | RCT, Open-label | esomeprazole |
| NCT05457270 A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers. | Healthy Volunteers | P1 | Completed | 30 | RCT, Open-label | AZD4831 |
| NCT05205161 A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | P1 | Terminated | 7 | Open-label | AZD0466 |
| NCT01568281 Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects | Safety, Pharmacokinetics | P1 | Completed | 58 | RCT, Open-label | Anastrozole ODF, Arimidex tablet, Anastrozole ODF, Arimidex tablet |
| NCT00526279 COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus | Hypertension | Completed | 9,000 | — | — | |
| NCT01215305 A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece | Gastroesophageal Reflux Disease | Completed | 600 | — | — | |
| NCT00871585 Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide | Advanced Prostate Cancer | Completed | 340 | — | — | |
| NCT00437853 Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer | Breast Cancer | N/A | Completed | 30 | Open-label | Anastrozole |
| NCT00660712 Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey | Bipolar Disorder | Completed | 1,018 | — | — | |
| NCT00247000 A Strategy of Home Telehealth for Management of Congestive Heart Failure(STARTEL) | Heart Failure | N/A | Completed | 150 | RCT, Open-label | — |
| NCT03696914 Intense Airway Eosinophilia in Asthma | Asthma, Eosinophilic Asthma | Completed | 918 | — | — | |
| NCT07446738 A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients | Chronic Rhinosinusitis With Nasal Polyps | Not Yet Recruiting | 200 | — | — | |
| NCT01298310 A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine) | Morton's Neuroma | Early P1 | Completed | 27 | RCT, Double-blind | Xylocaine, Xylocaine, Placebo |
| NCT01192659 Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Completed | 16,492 | — | — | |
| NCT04964908 Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | Completed | 1,088 | — | — | |
| NCT00608153 Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide | Essential Hypertension | Completed | 1,773 | — | — | |
| NCT00924183 Measuring Response to Depression Treatment | Depression | Unknown | 70 | — | — | |
| NCT01717105 Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients | Metastatic Non-Small-Cell Lung Cancer | Unknown | 225 | — | — | |
| NCT03084965 Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan | Type II Diabetes Mellitus | Completed | 1,987 | — | — | |
| NCT06243029 A Study to Assess Multidomain Endpoints of an ECG Patch | Acute Decompensated Heart Failure | Completed | 54 | — | — | |
| NCT02917057 Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment | Type 2 Diabetes | Completed | 6,024 | — | exenatide once weekly, basal insulin | |
| NCT07218172 Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | Severe Asthma | Completed | 197 | — | — | |
| NCT00551044 Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer | Prostatic Neoplasms | N/A | Completed | 42 | Open-label | Bicalutamide |
| NCT00952757 Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine | APS-related Hyperprolactinaemia, Schizophrenia | Completed | 35 | — | — | |
| NCT01062607 Study of the Clinical Management of Bipolar Disease | Bipolar Disorders | Completed | 2,965 | — | — | |
| NCT00997230 Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m | Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer | Completed | 4,243 | — | — | |
| NCT00722267 European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 7,400 | — | — | |
| NCT01986621 Myocardial Injury After Elective Coronary Stenting | Coronary Artery Disease | Completed | 530 | — | — | |
| NCT03798535 First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy | NSCLC | Completed | 1,156 | — | — | |
| NCT02368990 T790M Mutation Positive 2nd Line STandard of cAre Registry | Non Small Cell Lung Cancer | Withdrawn | — | — | — | |
| NCT01153399 A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer). | Non Small Cell Lung Cancer | Completed | 589 | — | — | |
| NCT02994511 Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials | Cancer | Unknown | 100 | — | — | |
| NCT04222465 Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients | Ovarian Neoplasms | Completed | 207 | — | — | |
| NCT00738998 Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors | Breast Cancer | N/A | Terminated | 102 | Open-label | — |
| NCT02578563 Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore | Diabetes Mellitus | Completed | 201 | — | — | |
| NCT02346292 Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement | COPD | Completed | 1,250 | — | — | |
| NCT06231693 Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil | Breast Cancer | Terminated | 2 | — | Trastuzumab deruxtecan | |
| NCT00928629 Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease | Peripheral Arterial Disease | N/A | Completed | 1,000 | Open-label | — |
| NCT01581372 A Community Based Approach to Dyslipidemia Management: Pharmacist Prescribing to Achieve Cholesterol Targets | Dyslipidemias | N/A | Completed | 100 | RCT, Open-label | — |
| NCT04801186 Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer | Metastatic Castration-resistant Prostates Cancer | Completed | 1,920 | — | — | |
| NCT02051166 Clinical Practice of AECOPD Management in China | Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Completed | 5,095 | — | — | |
| NCT01663974 Evaluation of Sub-syndromal Symptoms After Acute Depressive Episode in Bipolar Disorder | Bipolar Disorder, Sub-syndromal Symptoms | Terminated | 125 | — | — | |
| NCT04712890 Determination of Prevalence and Features of HRRm mCRPC (ADAM) | HRRm mCRPC | Completed | 331 | — | — | |
| NCT01342120 PHARMO Institute Seroquel Safety Study | Schizophrenia, Major Depressive Disorder | Completed | 18,325 | — | — | |
| NCT06652451 Covid-19 Data Analyses in Brazil | Covid | Completed | 361,000 | — | — | |
| NCT02271022 Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry | Acute Coronary Syndromes | Completed | 2,000 | — | — | |
| NCT02226822 DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan | Type 2 Diabetes Mellitus | Completed | 1,869 | — | — | |
| NCT04462900 Evaluate the Safety of Linaclotide in IBS-C Patients in China | Irritable Bowel Syndrome-IBS | Completed | 3,028 | — | — | |
| NCT00878930 Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer | Breast Cancer | Completed | 500 | — | — | |
| NCT00879736 A Study of the Effect of Patient Education (Talking Health Together) in Improving Doctor-patient Communication | Doctor-patient Communication Improvement | N/A | Completed | 322 | RCT, Single-blind | — |
| NCT02099565 Observational Prospective Study OPTIMA II - Follow-up | Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) | Completed | 572 | — | — | |
| NCT00679575 Statins and Risk of Myocardial Infarction in Real Life in France | Myocardial Infarction | Completed | 13,171 | — | — | |
| NCT04742192 Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | Completed | 601 | — | — | |
| NCT03562819 Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). | NSCLC (Non-small Cell Lung Cancer) | Completed | 268 | — | — | |
| NCT00660764 Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS) | Hypercholesterolemia, Coronary Heart Disease | Completed | — | — | Rosuvastatin | |
| NCT00738725 BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population | Plaque, Atherosclerotic Disease | Completed | 7,687 | — | — | |
| NCT04052113 Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer | Urologic Neoplasms | Completed | 152 | — | — | |
| NCT05667064 Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study | Unresectable Hepatocellular Carcinoma | Completed | 1,200 | — | — | |
| NCT07457151 Danicopan PMS in Korea | Paroxysmal Nocturnal Hemoglobinuria | Not Yet Recruiting | 8 | — | — | |
| NCT03934801 Expert Statements Concerning the Tapering of Oral Corticosteroids (OCS) for the Treatment of Asthma | Asthma | Completed | 140 | — | — | |
| NCT04241770 TURKish Acute Myocardial Infarction Registry | Acute Myocardial Infarction | Unknown | 1,930 | — | — | |
| NCT01888588 Risk of Uncomplicated Peptic Ulcer in the General Population | Peptic Ulcer [Iowa Type (107680.0010)] | Completed | 4,000 | — | Risk of symptomatic peptic ulcer | |
| NCT01775943 Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC | Lung Neoplasms | Unknown | 90 | — | — | |
| NCT05603845 Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients | Severe Asthma | Completed | 291 | — | — | |
| NCT04466969 Assessment of Hyperkalemia's Illness and Treatment Burden in Chronic Kidney Disease and Heart Failure Patients: HK Registry Pilot Study | Hyperkalemia | Completed | 146 | — | — | |
| NCT00282672 Ablation of Intestinal Metaplasia Containing Dysplasia | Barrett Esophagus | N/A | Completed | 127 | RCT, Single-blind | — |
| NCT03971175 Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC | Carcinoma, Non-Small-Cell Lung, Pathology, Molecular | N/A | Unknown | 540 | RCT, Double-blind | — |
| NCT04152941 Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients | Relapsed Ovarian Cancers Patients | Completed | 130 | — | Olaparib | |
| NCT05638646 A COPD Quality Improvement Program（QIP） | Chronic Obstructive Pulmonary Disease | N/A | Unknown | 1,107 | RCT, Open-label | — |
| NCT00864994 Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | Unknown | 60 | — | — | |
| NCT03156985 Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China | Type 2 Diabetes Mellitus | Completed | 3,000 | — | — | |
| NCT06767891 Real-world Study of Acalabrutinib | MCL, CLL | By Invite | 200 | — | — | |
| NCT00767247 Analysis of Antihypertensive Treatment Efficacy | Arterial Hypertension | Terminated | 2,000 | — | — | |
| NCT01081509 Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence | Breast Cancer | Completed | 1,077 | — | — | |
| NCT04272463 ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab | Severe Asthma | Completed | 217 | — | — | |
| NCT04514458 Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure | Heart Failure With Reduced Ejection Fraction | N/A | Completed | 1,410 | RCT, Double-blind | — |
| NCT06046534 Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs. | Systemic Lupus Erythematosus | Completed | 46 | — | — | |
| NCT02208921 An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes Patients | Diabetes | Completed | 3,000 | — | — | |
| NCT00963144 Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study | Gastroesophageal Reflux Disease | Completed | 250 | — | — | |
| NCT04814680 Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate | Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate From Digital Retinal Images | Completed | 301 | — | — | |
| NCT01936376 A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers | Head and Neck Cancer | Unknown | 150 | — | — | |
| NCT02991274 ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory | Locally Advanced or Metastatic EGFR(+) NSCLC Patients | Completed | 897 | — | — | |
| NCT04891978 US PRECISION Implementation Study | Asthma | N/A | Completed | 857 | Open-label | — |
| NCT04737382 Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. | Non-small-cell Lung Carcinoma | N/A | Unknown | 200 | Open-label | — |
| NCT03407196 Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey | Type 2 Diabetes Mellitus | Completed | 1,683 | — | Forxiga | |
| NCT02200627 Forxiga Tablets Specific Clinical Experience Investigation for Elderly | Type 2 Diabetes Mellitus | Completed | 1,724 | — | — | |
| NCT01841346 The First Jordanian PCI Registry: Events at 1 Year | Percutaneous Coronary Intervention | Completed | 2,000 | — | — | |
| NCT04525183 REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue | Ovarian Cancer, Fatigue | N/A | Completed | 49 | RCT, Open-label | — |
| NCT02230241 CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) | Dyslipidaemia | Completed | 2,700 | — | — | |
| NCT01176656 Hypoglycemia: Physician and Patient Perspectives | Type 2 Diabetes Mellitus, Hypoglycemia | Completed | 800 | — | — | |
| NCT00699959 National Survey on Coronary Patients and Heart Failure Performed in 2 Patient Groups | Coronary Patients, Heart Failure | Completed | 1,650 | — | — | |
| NCT00998062 Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain | Dyslipaemia, Atherosclerosis Risk | Completed | 30,181 | — | — | |
| NCT01971203 Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat | Major Depressive Disorder, Generalized Anxiety Disorder | N/A | Completed | 62 | RCT, Double-blind | seroquel xr |
| NCT01562665 Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf | Non Small Cells Lung Cancer | Completed | 25 | — | — | |
| NCT00750776 KvaliMed - a Quality Project With Focus on Patients in Antipsychotic Treatment | Antipsychotic Treatment, Quality Assurance | Terminated | 212 | — | — | |
| NCT00692133 Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment | Schizophrenia, Bipolar Disorder | Completed | 250 | — | — | |
| NCT03501615 An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia | Relapsed/Refractory Hairy Cell Leukemia | APPROVED_FOR_MARKETING | — | — | Moxetumomab Pasudotox | |
| NCT00922025 Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients | Non Small Cell Lung Cancer | Completed | 186 | — | — | |
| NCT01015625 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer | Synchronous Metastasized Breast Cancer, Circulating Tumor Cells | N/A | Completed | 90 | RCT, Open-label | — |
| NCT00402207 The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry | Asthma | N/A | Completed | 33 | RCT, Open-label | extrafine HFA-beclomethasone, HFA-fluticasone |
| NCT04696692 Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma | N/A | Completed | 60 | Open-label | — |
| NCT00831909 Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN | NSCLC | Completed | 3,513 | — | — | |
| NCT00587652 Methylene Blue Chromoendoscopy in Barrett's Esophagus | Barrett Esophagus | Completed | 100 | — | — | |
| NCT02015624 EYESHOT (EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian Coronary Care Units) | Acute Coronary Syndromes | Completed | 2,597 | — | — | |
| NCT01814943 The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users | Uncomplicated Peptic Ulcer | Completed | 39,000 | — | — | |
| NCT01077323 A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents | Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies) | Completed | 363,766 | — | exenatide, Other antidiabetic therapies | |
| NCT01209585 A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis | Arthritis | Completed | 23 | — | — | |
| NCT02316990 China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients | Stress Ulcers, Stress-related Mucosal Disease (SRMD) | Completed | 1,416 | — | — | |
| NCT02047526 A Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India | Heart Failure | Withdrawn | — | — | — | |
| NCT06283290 PROPE Severe Asthma Study in Egypt | Severe Asthma | Completed | 201 | — | — | |
| NCT06744374 A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US) | Pulmonary Disease, Chronic Obstructive | Completed | 22,369 | — | BGF, MITT | |
| NCT00686946 The National Register of Antipsychotic Medication in Pregnancy (NRAMP) | Pregnancy, Mental Disorders | Unknown | 500 | — | — | |
| NCT04068168 Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS) | Lung Cancer, Biliary Tract Cancer | Completed | 712 | — | — | |
| NCT00931320 Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients | Dyslipidemias | Completed | 3,000 | — | — | |
| NCT05462119 Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal Insufficiency | Hyperkalaemia | Completed | 887 | — | — | |
| NCT02292277 Ticagrelor Pharmacokinetics in NSTEMI | Myocardial Infarction | Completed | 63 | — | Ticagrelor |